ACTH(4–10) comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-04-20. Numbers and descriptions here follow the published literature rather than marketing material.
Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.
Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.
该化合物于二十世纪八十年代在俄罗斯被开发，相关工作由俄罗斯科学院分子遗传学研究所的研究团队主导。开发目标并非复制 ACTH 的完整激素活性，而是寻找保留其神经作用方向、同时去除促肾上腺皮质激素释放效应的短肽片段。研究记录显示，这一方向促成了多个相关短肽的合成与筛选，而 Semax 是其中被研究最广泛的一个。当地文献常以 Семакс 这一名称指代它。
研究兴趣主要集中在神经营养因子相关的路径上，包括脑源性神经营养因子与神经生长因子的表达变化。部分实验报告称在特定条件下观察到这些因子的水平上升，但具体信号通路和剂量依赖关系仍未完全厘清。多数公开数据来自细胞模型和动物实验，人体对照研究数量有限。因此，该化合物的作用机制在文献中属于活跃讨论，而非已经确立的定论。
Semax 是一种人工合成的七肽，氨基酸序列为 Met-Glu-His-Phe-Pro-Gly-Pro，单字母缩写记作 MEHFPGP。它被归类为促肾上腺皮质激素片段 ACTH(4-10) 的结构类似物，但并不天然存在于生物体内。母体片段 ACTH(4-10) 的序列为 Met-Glu-His-Phe-Arg-Trp-Gly，Semax 替换了中间两个残基，并在羧基端延长了 Pro-Gly-Pro 三肽。这种延长被普遍认为能提升分子对肽酶的耐受性。
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Seven-residue peptide |
| Molecular mass | 813.9 Da | Monoisotopic value |
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Freely soluble in water | Also soluble in saline and polar solvents |
| Storage (dry) | -20 °C or lower | Desiccated, protected from light |
Reported pharmacological work centers on neurotrophic signaling, including changes in BDNF and NGF expression in hippocampal tissue in animal models. Human data come largely from studies conducted in Russia, and how well those results generalize to other populations remains an open question. Regulatory status differs sharply by jurisdiction: Semax is a registered prescription medicine in Russia, while it holds no approved marketing status in the United States or the European Union. Outside such jurisdictions it is generally handled as a research chemical, which affects both documentation and quality expectations.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.
Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
=== Type 2 diabetes === GLP-1 agonists were initially developed to treat type 2 diabetes. The 2025 American Diabetes Association (ADA) standard of care in diabetes include GLP-1 agonists or SGLT2 inhibitors as a first-line pharmacological therapy for type 2 diabetes in people who have or are at high risk for atherosclerotic cardiovascular disease or heart failure. The ADA also recommends GLP-1 agonists for people with both type 2 diabetes and kidney disease. GLP-1 agonists and SGLT2 inhibitors can be combined with metformin, which has shown an enhanced lowering of A1C. GLP-1 receptor agonists are not recommended for use in combination with DPP-4 enzyme inhibitors due to lack of evidence. One advantage of GLP-1 agonists over older insulin secretagogues such as sulfonylureas or meglitinides is that they have a lower risk of hypoglycemia, while improving weight and cardiovascular and kidney health. ADA also recommends use of GLP-1 agonists instead of starting insulin therapy in people with type 2 diabetes who need additional glucose control, except when catabolism, hyperglycemia, or autoimmune diabetes is suspected. A 2021 meta-analysis reported a 12% reduction in all-cause mortality when GLP-1 agonists are used in the treatment of type 2 diabetes, as well as significant improvements in cardiovascular and renal outcomes relative to nonusers.
After acetylation, the solvent is evaporated to remove the acetic anhydride, and finally water is added. The amount of water added depends on the amount of plant material used in the beginning of the process, most often 30 milliliters per kilogram of dry plant material. Although the drug is primarily intended for intravenous injection, kompot extraction as described here produces an end product containing residual plant matter, waste chemicals, impure water, and other contaminants, making this a dangerous substance to inject since such impurities can lead to abscesses or anaphylactic shock. Use of Polish heroin has been in decline since the break-up of the Soviet Union and its Central and Eastern European satellite states (Hungary, Poland, Czechoslovakia, Romania, et al.) as after 1991 the availability of heroin and other drugs smuggled into those countries from abroad increased enormously. Since then, in Poland "kompot"/"Polish heroin" has all but disappeared, except in a few rural areas where cheaper, purer, more potent drugs have not overwhelmed the illicit marketplace. In Belarus, compote is the most popular psychoactive substance among people on the list of narcological supervision in health care facilities. In 1998 they constituted 75.8% of registered persons, and in 2012 - 53%, and their number increased 2.5 times in the years 1998–2012.
The Brazilian press was officially born in Rio de Janeiro on 13 May 1808 with the creation of the Royal Printing National Press by the Prince Regent John. The Gazeta do Rio de Janeiro, the first newspaper published in the country, began to circulate on 10 September 1808. The largest newspapers nowadays are Folha de S.Paulo, O Globo, and O Estado de S. Paulo. Radio broadcasting began on 7 September 1922, with a speech by then President Epitácio Pessoa, and was formalized on 20 April 1923 with the creation of the "Radio Society of Rio de Janeiro". Television in Brazil began officially on 18 September 1950, with the founding of TV Tupi by Assis Chateaubriand. Since then, television has grown in the country, creating large commercial broadcast networks such as Globo, SBT, RecordTV, Bandeirantes and RedeTV. By the mid-1960s, Brazilian universities had installed mainframe computers from IBM and Burroughs Large Systems. In the 1970s and 1980s, the Brazilian government restricted foreign imports to protect the local manufacturing of computers. In the 1980s, Brazil produced half of the computers sold in the country. By 2009, the mobile phone and Internet use in Brazil was the fifth largest in the world. As of early 2025, internet penetration in Brazil stood at 86.2% of the total population (183 million individuals), and the ratio of cellular mobile connections to the total population was 102% (217 million active connections). In May 2010, the Brazilian government launched TV Brasil Internacional, an international television station, initially broadcasting to 49 countries.
If one were to flip a fair coin five times and get heads each time, it would not be any more likely for a sixth flip to come up tails. Phrased another way, after a long and/or unlikely streak of independently random events, the probability of the next event is not influenced by the preceding events. Humans often feel that the underrepresented outcome is more likely, as if it is due to happen. Such thinking may be attributed to the mistaken belief that gambling, or even chance itself, is a fair process that can correct itself in the event of streaks.
Sources: en.wikipedia.org
==== Acquisitions and mergers ==== In June 2000, Pfizer acquired Warner-Lambert outright for $116 billion. To satisfy conditions imposed by antitrust regulators at the Federal Trade Commission, Pfizer sold off or transferred stakes in several minor products, including RID (a shampoo for treatment of head lice, sold to Bayer) and Warner-Lambert's antidepressant Celexa (which competes with Zoloft). The acquisition created what was, at the time, the second-largest pharmaceutical company worldwide. In 2003, Pfizer merged with Pharmacia, and in the process acquired Searle and SUGEN. Searle had developed Flagyl (metronidazole), a nitroimidazole antibiotic medication used particularly for anaerobic bacteria and protozoa. Searle also developed celecoxib (Celebrex) a COX-2 inhibitor and nonsteroidal anti-inflammatory drug (NSAID) used to treat the pain and inflammation in osteoarthritis, acute pain in adults, rheumatoid arthritis, ankylosing spondylitis, painful menstruation, and juvenile rheumatoid arthritis. SUGEN, a company focused on protein kinase inhibitors, had pioneered the use of ATP-mimetic small molecules to block signal transduction. The SUGEN facility was shut down in 2003 by Pfizer, with the loss of more than 300 jobs, and several programs were transferred to Pfizer. These included sunitinib (Sutent), a cancer medication which was approved for human use by the FDA in January 2006. A related compound, SU11654 (Toceranib), was also approved for cancer in dogs, and the ALK inhibitor Crizotinib also grew out of a SUGEN program.
==== Information and Infrastructure Development ==== In 2013, Lad was appointed as Minister of State for Information and Infrastructure Development in the Congress government headed by Chief Minister Siddaramaiah. As minister in charge of Dharwad district, Lad was involved in reviewing district-level development and administrative issues.
Zita of Bourbon-Parma (Zita Maria delle Grazie Adelgonda Micaela Raffaela Gabriella Giuseppina Antonia Luisa Agnese; 9 May 1892 – 14 March 1989) was the last Empress of Austria and Queen of Hungary, in addition to other titles. She ascended to these titles when her husband, Charles I, became the last monarch of Austria-Hungary. She was declared Servant of God by Pope Benedict XVI. Born as the seventeenth child of the dispossessed Robert I, Duke of Parma, by his second wife, Infanta Maria Antonia of Portugal, Zita married Archduke Charles of Austria in 1911. Charles became heir presumptive to Emperor Franz Joseph I in 1914 after the assassination of his uncle Archduke Franz Ferdinand of Austria, and acceded to the throne in 1916 after the elderly emperor's death. After the end of World War I in 1918, the Habsburgs were deposed and the former empire became home to the states of Austria, Hungary, and Czechoslovakia, while other parts were annexed to or joined the Kingdom of the Serbs, Croats and Slovenes, Italy, Romania, and a reconstituted independent Poland. Charles and Zita left for exile in Switzerland and, after the failure of attempts to restore royal rule in Hungary, were subsequently removed from that country by the Allies to Madeira, where Charles died in 1922. After her husband's death, Zita and her son Otto served as symbols of unity for the exiled dynasty. A devout Catholic, she raised a large family after being widowed at the age of 29; she never remarried.
A single-molecule electrically operated motor made from a single molecule of n-butyl methyl sulfide (C5H12S) has been reported. The molecule is adsorbed onto a copper (111) single-crystal piece by chemisorption.
Immunogen — an antigen that is capable of inducing an immune response, i.e., it is immunogenic. Antigen is often used interchangeably with this term, but this is not, strictly speaking, correct. All immunogens are antigens, but not all antigens are immunogens. The antigen within a vaccine is often referred to as an immunogen, even if, strictly speaking, its purified form cannot induce immune responses (requiring adjuvants to do so). For simplicity, many sources use the term "antigen" in place of "immunogen," but these terms should not be regarded as interchangeable. Allergen – A substance capable of causing an allergic reaction in sensitized individuals. The reaction may result after exposure via ingestion, inhalation, injection, or contact with skin. Tolerogen – A substance that invokes immune tolerance. This property is related to its molecular properties and circumstances such as route of administration. Superantigen – A class of antigens that cause non-specific activation of T-cells, resulting in polyclonal T-cell activation and massive cytokine release. Immunoglobulin-binding protein – Proteins such as protein A, protein G, and protein L that are capable of binding to antibodies at positions outside of the antigen-binding site (paratope). These are sometimes known as B cell superantigens. Epitope – The specific part of an antigen that is bound by an antibody (or T cell receptor), its antigenic determinant.Antigenic molecules, normally "large" biological polymers, usually present surface features that can act as points of interaction for specific antibodies.
Sources: en.wikipedia.org
It is a synthetic peptide of seven amino acids. Its backbone corresponds to a fragment of adrenocorticotropic hormone extended at the carboxyl end. The material is distributed as a lyophilized solid for laboratory use.
The extension was introduced to slow enzymatic breakdown of the peptide in biological systems. Natural ACTH fragments are degraded rapidly by peptidases. Adding the tripeptide was intended to extend the window during which the molecule remains intact.
Most published work consists of animal experiments conducted in a small number of laboratories. Human data are limited in number and size. Whether the observed effects translate into reliable clinical benefit is still unresolved.
不是。Semax 是完全人工合成的七肽，自然界中没有对应的已知肽段。它的设计灵感来自促肾上腺皮质激素片段 ACTH(4-10)，但序列经过了替换和延长。